BACCHUS: Blood Screening for Adult Colorectal Cancer

Sponsor
University Hospital, Lille (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05577143
Collaborator
Ministry of Health, France (Other)
303
24

Study Details

Study Description

Brief Summary

Multicenter, inter-regional, case-control study with the primary objective of evaluating the discriminative power of the blood biomarker TFPI-1 to separate patients with histologically proven CRC from an asymptomatic control population between 50 and 75 years of age with normal colonoscopy.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    303 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Evaluation of the Discriminatory Role of Blood TFPI-1 and TFPI-2 in Adult Colorectal Cancer
    Anticipated Study Start Date :
    Oct 1, 2022
    Anticipated Primary Completion Date :
    Oct 1, 2024
    Anticipated Study Completion Date :
    Oct 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Case group

    All consecutive patients from participating centers with an abnormal colonoscopy (presence of mucosal lesions at endoscopy), with histological confirmation of colorectal cancer. These will be patients with one or more histologically confirmed adenocarcinomatous lesions (CRC+) located in the colonic frame or rectum, with or without synchronous liver metastases.

    Control group

    All consecutive patients between 50 and 75 years of age for whom colonoscopy will be normal (no mucosal lesions). In this situation, histological examination is not performed.

    Polyp group

    All consecutive patients for whom colonoscopy shows mucosal lesions that will be classified as polyps after histological examination.

    Outcome Measures

    Primary Outcome Measures

    1. Area under the ROC curve (AUC) of the TFPI-1 biomarker [At 2 months]

      the AUC of the TFPI-1 biomarker to separate the 2 groups (CRC+ and control, i.e., asymptomatic population between 50 and 75 years with normal colonoscopy).

    Secondary Outcome Measures

    1. AUC of the TFPI-2 biomarker to separate the 2 groups (CRC+ and control). [At 2 months]

    2. AUC of the discriminant score constructed by logistic regression with the 2 blood biomarkers as explanatory variables and the group type (CRC+ and control) as the variable to be explained. [At 2 months]

    3. Extension of c-index to the 3-group case proposed by Van Calster B et al. [At 2 months]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with suspected colorectal cancer for which colonoscopy is indicated.

    • Patients between 50 and 75 years old, asymptomatic from the digestive point of view (for example referred for colonoscopy as part of a pre-operative check-up of an inguinal hernia or 3 months after an episode of complicated sigmoiditis), for whom a follow-up colonoscopy is indicated.

    Note.

    • If the post-inclusion colonoscopy is normal, no biopsy will be performed and patients will be assigned to the control group.

    • If the colonoscopy performed after inclusion is abnormal (presence of at least one mucosal lesion), patients will be assigned to the "colorectal cancer" group or to the "polyps" group depending on the results of the anatomopathological analysis of the lesion(s)

    Exclusion Criteria:
    • All clinical situations outside of CRC that could increase TFPI-1 or 2 blood levels: acute coronary syndrome (unstable angina, acute myocardial infarction), severe sepsis, decompensated cirrhosis, pregnancy, chronic inflammatory bowel disease (Crohn's or ulcerative colitis), colitis or radiation rectitis.

    • Endoscopic polypectomy without prior histological confirmation.

    • Emergency (occlusion or peritonitis)

    • Minor patients.

    • Persons of full age under legal protection or unable to express their consent

    • Persons not affiliated to a social security system or beneficiaries of such a system.

    • Pregnant women, women in labor or nursing mothers.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University Hospital, Lille
    • Ministry of Health, France

    Investigators

    • Principal Investigator: Philippe ZERBIB, MD,PhD, University Hospital, Lille

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Lille
    ClinicalTrials.gov Identifier:
    NCT05577143
    Other Study ID Numbers:
    • 2021_0220
    • 2022-A00223-40
    First Posted:
    Oct 13, 2022
    Last Update Posted:
    Oct 13, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Lille
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 13, 2022